Tim Knotnerus is the founder of AgomAb Therapeutics. AgomAb Therapeutics has raised $189M in total funding. Latest round: Series D. Based in Ghent, Belgium.
Tim Knotnerus is the Chief Executive Officer at AgomAb Therapeutics, a company focused on developing therapies to treat fibrosis and regenerate tissue in chronic conditions like fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis. AgomAb has successfully raised significant funding, including a $100 million Series C in 2023 and an $89 million Series D in 2024, to advance its pipeline of drug candidates.
Full founder directory · Investor directory · Company funding database · Fundraising library